Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib + Chemotherapy in Early Stage TNBC
NCT03812393Phase 2Active, not recruiting
- Sponsor
- West Cancer Center & Research Institute
- Start
- Jun 2019
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neratinib in triple-negative breast cancer (TNBC), sponsored by West Cancer Center & Research Institute. Primary endpoints: Percentage of patients experiencing >= 20% response to neratinib only therapy at 4 weeks and Pathologic Complete Response at 15 weeks. Started Jun 2019; status: active, not recruiting.
02
Drugs
neratinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03812393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812393.